Holding company and industrial conglomerate Icahn (NYSE: IEP) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 5.3% year on year to $2.32 billion. Its GAAP loss of $0.30 per share was significantly below analysts’ consensus estimates.

Is now the time to buy IEP? Find out in our full research report (it’s free).

StockStory’s Take

Icahn Enterprises reported second quarter results that fell below Wall Street expectations, with both revenue and GAAP profitability missing analyst estimates. Management attributed the challenging quarter to mixed performance across its portfolio, highlighting operational headwinds in its energy and auto service businesses. CEO Andrew Teno pointed to negative impacts from refining mark-to-market adjustments and ongoing turnaround efforts in the energy segment, while also noting gradual revenue improvement in the auto service division. Cost pressures and operational inefficiencies were cited as key obstacles across several core segments.

Looking ahead, management expects improved performance as operational initiatives and restructuring plans move forward. The company is particularly focused on accelerating auto service recovery, progressing the pivotal clinical trial in its pharma portfolio, and leveraging strong liquidity to pursue new investment opportunities. Teno emphasized, "We have a significant war chest to take advantage of opportunities as they arise," while cautioning that further restructuring and market volatility could still weigh on near-term results.

Key Insights from Management’s Remarks

Management highlighted mixed results across core businesses, with energy turnaround and restructuring in food packaging weighing on margins. Progress in auto services and pharma trial initiation were cited as longer-term positives.

• Energy segment volatility: The energy business saw negative EBITDA, primarily due to unfavorable renewable identification number (RIN) mark-to-market adjustments and lower throughput from refinery maintenance earlier in the year. Management noted some relief from improved crack spreads and the expectation of no further major turnarounds through 2026.
• Auto service division turnaround: The auto service business began to show early signs of stabilization, with year-over-year revenue improving from a 5% decline in the previous quarter to modest growth in May and June. Initiatives such as increased investment in labor, equipment, and facilities are beginning to positively impact average transaction value and customer experience.
• Pharma clinical trial launch: The company initiated a pivotal clinical trial for VIVUS's pulmonary arterial hypertension asset (VI-0106), targeting a disease with limited treatment options. Management believes this asset could be disease-modifying, but early data will not be available for 12 to 18 months.
• Food packaging restructuring impacts: Operational inefficiencies and lower volumes continued to hamper the food packaging segment, with management warning that restructuring disruptions will persist until late 2025. These headwinds are expected to temporarily weigh on segment profitability.
• Portfolio repositioning and liquidity: Icahn Enterprises highlighted recent progress at portfolio companies, including management transitions at CVI and successful divestitures at SWX's utility services division. The holding company maintains significant liquidity, which management views as a competitive advantage for future investments.

Drivers of Future Performance

Icahn Enterprises expects margin recovery and portfolio repositioning to drive future performance, though restructuring and external market factors remain risks.

• Operational improvements underway: Management is prioritizing cost controls and efficiency initiatives, particularly in the auto service and food packaging segments. These actions are intended to gradually restore margins and support long-term profitability.
• Pharma pipeline milestones: The outcome of the VIVUS clinical trial for pulmonary arterial hypertension represents a potential inflection point for the pharma segment, but meaningful results are not expected until at least late 2026, leaving near-term growth dependent on other divisions.
• Market and regulatory uncertainties: The company faces ongoing external risks, including energy market volatility and unresolved regulatory issues such as the RIN litigation. Management remains hopeful for a positive resolution, which could significantly reduce liabilities and improve cash flow, but timing remains uncertain.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will be focused on (1) execution of turnaround initiatives in the auto service and food packaging segments, (2) updates on the VIVUS clinical trial for pulmonary arterial hypertension, and (3) progress in portfolio repositioning, including management transitions and potential divestitures. The timing and resolution of regulatory issues in energy, as well as capital deployment decisions, will also be closely monitored as key indicators of strategic momentum.

Icahn Enterprises currently trades at $9.20, up from $8.98 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.